Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023 07:34 ET
|
Pharvaris N.V.
ZUG, Switzerland, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023 06:51 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
August 23, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 06:50 ET
|
Pharvaris N.V.
Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3...
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
July 21, 2023 10:20 ET
|
Pharvaris N.V.
ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
June 26, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary...
Pharvaris Announces $70 Million Private Placement Financing
June 20, 2023 06:50 ET
|
Pharvaris N.V.
ZUG, Switzerland, June 20, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor...
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
June 10, 2023 18:01 ET
|
Pharvaris N.V.
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo ZUG,...